Hospitals are sitting on a quiet competitive advantageand many are ignoring it.
In the pharmaceutical market, patent expiration isnt just a legal milestone. Its a pricing event. A supply-chain inflection point. A formulary strategy fork in the road. An…

Generic launches dont just happen. Theyre engineered by timelines, filings, and legal leverage.
If youre still forecasting generic drug launch dates using spreadsheets and historical averages, youre already behind. In todays market, the difference be…

The Orange Book Isnt Just a Database. Its a Talent Map.
If youre trying to find the next wave of pharma innovation, you dont start with a pitch deckyou start with the paper trail.
The FDAs Orange Book is often treated like a compliance tool: patents, e…

Biotech investors love pipeline value, but most portfolio rankings still miss the point.
A company can have a long list of programs and still be quietly destroying valuebecause the timing and probability of cash flows are treated like afterthoughts. In…

The patent cliff isnt just a pharma problemits a talent problem.
Most people talk about the patent cliff as a revenue event: when exclusivity ends, generic competition arrives, margins compress, and pipelines suddenly look urgent. But theres another cl…

Stop Overstocking: How Patent Intelligence Helps Wholesalers Reduce Branded Drug Inventory Risk
Branded drug inventory risk isnt just a finance problemits a timing problem.
In wholesaling, the margin story can flip overnight when a branded product appr…

Big Pharma doesnt always announce its next workforce shift. Sometimes it whispersthrough patents.
Heres the hidden hiring signal many leaders miss: patent cliff events dont just reshape revenue forecasts. They reshape headcount decisions, contractor sp…

Biosimilar sourcing isnt a procurement problemits a patent strategy problem.
If youre planning a switch from an originator to a biosimilar, the hardest part usually isnt identifying candidates. Its timing the switch so you capture volume and margin bef…

Pharma has a new way to sell the same storyjust with a different price tag.
In a world where patients are increasingly asked to wait for innovation, drugmakers are finding another lever: repurposed medicines. The molecules may be old. The indication ma…

Pharma recruiting is broken in a very specific way: most teams still treat best scientists like a vibe instead of a measurable signal.
If youve ever watched a search committee chase the same handful of CV buzzwordspatent experience, publication record,…